WEDNESDAY, Nov. 24 (HealthDay News) -- There's encouraging news
for women with epilepsy who want to nurse their babies. Children
whose mothers took certain anti-seizure medications while
breast-feeding don't appear to suffer any negative cognitive
effects by age 3, a new study finds.
The multi-center study looked at nearly 200 children whose
mothers took one of four common antiepileptic drugs, and found no
difference in IQ levels at age 3 among those who were breast-fed
"For women who have epilepsy, this is one less thing that they as new mothers have to worry about," said lead author Dr. Kimford Meador, a professor of neurology at Emory University in Atlanta. The study was published in the Nov. 24 online edition and in the Nov. 30 print issue of the journal Neurology.
The findings are part of the Neurodevelopmental Effects of
Antiepileptic Drugs study, an ongoing trial looking at the
long-term cognitive effects on children whose mothers took one of
four common antiepilepsy meds during and after their pregnancies:
carbamazepine (Carbatrol, Equetro, Tegretol, Tegretol XR),
lamotrigine (Lamictal), phenytoin (Dilantin, Phenytek) or valproate
(Depakote, Depakote ER, Depakene).
For the study, Meador and his colleagues examined the results of
IQ tests given to 199 three-year-olds whose mothers entered the
trial while they were still pregnant. A total of 194 women at 25
epilepsy centers were enrolled in the study from 1999 to 2004, and
there were five sets of twins.
Forty-two percent of the babies were breast-fed, for an average
of six months, and mothers who breast-fed tended to have higher
average IQs than those who didn't (104 versus 95). After
controlling for the mother's IQ, the researchers found that the
average IQ in the breast-fed group of children was 99, versus 98 in
the non-breast-fed group.
The new study on breast-feeding comes after other research
suggesting hazards to the developing fetus from exposure to one
anti-seizure medication. Last year, the researchers reported that
babies who were exposed to the drug valproate in utero had IQs at
age 3 that were an average of 9 points lower than babies whose
mothers took one of the other three drugs during pregnancy. They
also found that the effect was dose-dependant, meaning the higher
the dose of valproate, the lower the IQ. Other studies have shown
that exposure to valproate during the first trimester can increase
the risk of birth defects.
Meador speculated that one reason there was no difference in IQ
levels among breast-fed and formula-fed babies exposed to valproate
may be because "the level of the drug in the infants' bloodstreams
was very much lower than it was during pregnancy."
Dr. Autumn Klein is director of the Program in Women's Neurology
at Brigham and Women's Hospital in Boston, and the author of an
editorial accompanying the study. She said the study "provides the
most information thus far" when it comes to counseling women who
take antiepilepsy drugs on the risks of breast-feeding.
Klein believes the findings "will definitely change" people's
attitudes toward the use of these drugs during breast-feeding.
Right now, she said, many doctors do not recommend breast-feeding
for women taking the medications "due to the largely unknown
effects of [antiepilepsy drugs] during breast-feeding."
Dr. Jacqueline French, a professor of neurology at New York
University School of Medicine who treats many women with epilepsy,
said the findings were reassuring in that, "even if a drug produces
problems in utero, it doesn't produce additional problems for the
baby during breast-feeding," she said.
French said another possibility for the difference seen in
valproate exposure in utero versus during breast-feeding may be
that "the brain is developing incredibly rapidly in utero, and so
that may be a very sensitive time for exposure to valproate."
Meador cautioned that the results were preliminary and that
additional studies covering a wider range of antiepilepsy drugs are
"We studied the four most commonly used drugs in our epilepsy centers during the time the women were enrolled," he said. "We're now hoping to get additional funding to go and look at other drugs."
The study was funded by the U.S. National Institutes of Health
and the U.K. Epilepsy Research Foundation.
There's more on epilepsy and pregnancy at the
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.